AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00839046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Filter
Description: Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
Study NCT00839046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air Filter and Air Conditioner
Description: Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
Study NCT03926559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine.
Description: Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
Study NCT01700517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: spinal anesthesia
Study NCT01700517 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Spinal anesthesia
Description: spinal anesthesia
Study NCT01700517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Femoral nerve block
Study NCT01700517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sciatic nerves block
Description: sciatic nerves block
Study NCT02858609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Swab
Study NCT01236612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study NCT01236612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine prophylaxis
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study NCT01236612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
Study NCT01236612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunization
Description: Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
Study NCT01236612 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmodium falciparum Bloodstage challenge
Description: Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
Study NCT01236612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Bloodstage challenge
Description: Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
Study NCT01236612 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasmodium falciparum mosquito challenge
Description: Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01466881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01466881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01236612 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasmodium falciparum mosquito challenge
Description: Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
Study NCT01236612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT01466881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00391755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: 1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary
Study NCT00391755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ramelteon
Description: 1. ramelteon 8mg po qhs with sleep and headache diary~2. placebo 1 po qhs with sleep and headache diary
Study NCT01236612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT01236612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study NCT03219593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablets
Description: Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
Study NCT00471445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine/amitriptyline NP-H cream
Description: Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
Study NCT00471445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study NCT03629418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted blood-pressure management
Description: Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
Study NCT03629418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine blood-pressure management
Description: Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
Study NCT01433627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trans-radial and short-term bivalirudin
Description: trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
Study NCT01433627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trans-radial and long-term bivalirudin infusion
Description: Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
Study NCT01433627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trans-radial and standard of care pharmacology
Description: Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
Study NCT01433627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans-femoral and Short-term bivalirudin
Description: Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI.
Study NCT01433627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trans-femoral and long-term bivalirudin infusion
Description: Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group.
Study NCT01433627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trans-femoral and standard of care pharmacology
Description: Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
Study NCT05434247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle choice
Description: The type of needle use was the only intervention
Study NCT05434247 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Needle choice
Description: The type of needle use was the only intervention
Study NCT02327286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promote and support healthy behaviors
Description: * Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices.
Study NCT03645408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Subject received an injection of 5 mcg of immediate release exenatide.
Study NCT03645408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham injection
Description: Subjects received a sham injection with no study drug.
Study NCT03126539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
Study NCT03126539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Narrow-band Ultraviolet B exposure
Description: The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
Study NCT03126539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 mm skin punch biopsy
Description: All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
Study NCT00308438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide (ALX-0600)
Description: 0.1 mg/kg injected subcutaneously daily
Study NCT03121131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Exam Findings
Description: Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
Study NCT03121131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inaccurate Clinical Exam Findings
Description: Inaccurate findings are given to the radiologists
Study NCT03121131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No clinical exam findings
Description: No clinical exam findings are given to the radiologists
Study NCT04017169 — intervention group
Intervention type: OTHER
Intervention: No intervention as observational study
Study NCT01028911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654746
Description: PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
Study NCT01028911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
Study NCT04089410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand.
Study NCT04089410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of Cardiorespiratory Fitness
Description: An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
Study NCT03178721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: study B regulatory in blood and its correlation with atherosclerosis
Study NCT04939077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Description: In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
Study NCT03239756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection
Study NCT04293042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BK-virus specific CTLs
Description: HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg).
Study NCT01577160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
Study NCT01067508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiji Water
Description: Participants are asked to drink one liter of this silicon-rich water daily for three months.
Study NCT00975702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC by Inflation of Pneumatic Tourniquet
Description: Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
Study NCT03917719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent
Description: 100 mg/kg/day
Study NCT02528500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
Description: Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Study NCT02683616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous Positive Airway Pressure in cases of moderate/severe OSA
Study NCT01763476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-coated balloon angioplasty
Description: plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
Study NCT01763476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atherectomy
Description: atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basiliximab
Description: Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Study NCT00543569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Study NCT02179528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study NCT01389648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre Operative
Description: Pre operative chest physiotherapy treatment
Study NCT02919488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Condition
Description: A bout of exercise in the evening followed by high-sugar meal consumption the following morning